Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine

Annals of Internal Medicine

Volumn 129, Issue 9, 1998, Pages 716-718

  Black, Alison J ^a,c   McLeod, Howard L ^a,b   Capell, Hillary A ^a,d   Powrie, Robert H ^a   Matowe, Lloyd K ^a   Pritchard, Stuart C ^a   Collie Duguid, Elaina S R ^a   Reid, David M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c NHS GRAMPIAN   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ADULT; ALLELE; ARTICLE; BLOOD TOXICITY; COST EFFECTIVENESS ANALYSIS; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHEUMATIC DISEASE; SCREENING TEST; TREATMENT PLANNING;

EID: 0032212759     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-9-199811010-00007     Document Type: Article

References (14)

1. Gomez-Reino JJ. Long-term therapy for rheumatoid arthritis. Lancet. 1996; 347:343-4.
2. Hollander AA, van Saase JL, Kootte AM, van Dorp WT, van Bockel HJ, van Es LA, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet. 1995;345:610-4.
3. Pearson DC, May GR, Fink GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123: 132-42.
4. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis [Letter]. Lancet. 1997;350:261.
5. Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med. 1995;123: 32-4.
6. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131:193-7.
7. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [Letter]. Lancet. 1993;341:1151.
8. McLeod HL, Lin JS, Pui CH, Scott EP, Evans WE. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther. 1994;55:15-20.
9. Schütz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient [Letter]. Lancet 1993;341:436.
10. McLeod HL, Rolling MV, Liu Q, Pui CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995;85:1897-902.
11. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126:608-14.
12. Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. [In press].
13. Kerstens PJ, Stolk JN, Hilbrands LB, van de Putte LB, De Abreau RA, Boerbooms AM. 5-nucleotidase and azathioprine-related bone-marrow toxicity [Letter]. Lancet. 1993;342:1245-6.
14. Bergan S, Rugstad HE, Klemetsdal B, Giverhaug T, Bentdal O, Sodal G, et al. Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells. Ther Drug Monit. 1997;19:318-26.